Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24759661 | 0.89 | MCHR1 (0.56) | MCHR1KCNH2 | |
| SCHEMBL4888598 | 0.78 | MCHR1 (0.57) | MCHR1KCNH2 | |
| SCHEMBL4779640 | 0.78 | MCHR1 (0.57) | MCHR1KCNH2 | |
| SCHEMBL4731548 | 0.71 | MCHR1 (0.60) | MCHR1KCNH2 | |
| SCHEMBL15111890 | 0.71 | MCHR1 (0.81) | MCHR1 | |
| SCHEMBL4796254 | 0.70 | MCHR1 (0.67) | MCHR1KCNH2 | |
| SCHEMBL4879844 | 0.70 | MCHR1 (0.67) | MCHR1KCNH2 | |
| SCHEMBL4886463 | 0.70 | MCHR1 (0.64) | MCHR1KCNH2 | |
| SCHEMBL2892570 | 0.70 | MCHR1 (1.00) | MCHR1KCNH2 | |
| SCHEMBL15111179 | 0.70 | MCHR1 (0.81) | MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373969-A1 | MK2 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230265076-A1 | MK2 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2023-08-24 | — | — | US | disclosed |
| US-11680056-B2 | MK2 inhibitors and uses thereof | XINTHERA, INC. (US) | 2023-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373969-A1 | MK2 INHIBITORS AND USES THEREOF | MKNK2, ENPP2, MAPKAPK2 | MCHR1 4509/4885KCNH2 2197/4885 |
| US-11680056-B2 | MK2 inhibitors and uses thereof | MKNK2, ENPP2, MAPKAPK2 | MCHR1 4509/4885KCNH2 2197/4885 |
| US-20230265076-A1 | MK2 INHIBITORS AND USES THEREOF | MKNK2, ENPP2, MAPKAPK2 | MCHR1 4509/4885KCNH2 2197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.